Abstract
A37 N-803 Plus Nivolumab for Advanced or Metastatic Non-Small Cell Lung Cancer: Update on Phase II Experience of Combination PD1 Blockade with an IL-15 Superagonist
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have